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Parkinson’s disease (PD) is the second most common neurodegenerative disease, charac-
terized by the degeneration of midbrain dopaminergic (mDA) neurons and their axons, and
aggregation of α-synuclein, which leads to motor and late-stage cognitive impairments. As
the motor symptoms of PD are caused by the degeneration of a specific population of mDA
neurons, PD lends itself to neurotrophic factor therapy. The goal of this therapy is to apply a
neurotrophic factor that can slow down, halt or even reverse the progressive degeneration
of mDA neurons. While the best known neurotrophic factors are members of the glial cell
line-derived neurotrophic factor (GDNF) family, their lack of clinical efficacy to date means
that it is important to continue to study other neurotrophic factors. Bonemorphogenetic pro-
teins (BMPs) are naturally secreted proteins that play critical roles during nervous system
development and in the adult brain. In this review, we provide an overview of the BMP lig-
ands, BMP receptors (BMPRs) and their intracellular signalling effectors, the Smad proteins.
We review the available evidence that BMP–Smad signalling pathways play an endogenous
role in mDA neuronal survival in vivo, before outlining how exogenous application of BMPs
exerts potent effects on mDA neuron survival and axon growth in vitro and in vivo. We dis-
cuss the molecular mechanisms that mediate these effects, before highlighting the potential
of targeting the downstream effectors of BMP–Smad signalling as a novel neuroprotective
approach to slow or stop the degeneration of mDA neurons in PD.
Introduction
Dopamine is one of the major catecholaminergic neurotransmitters found in the adult brain. Seventy-five
percent of all dopaminergic neurons are found in the midbrain, with an estimated 400000 to 600000 in
the humanmidbrain [1–3]. During development, the generation and differentiation of dopaminergic neu-
rons are regulated by a complex, temporally regulated pattern of gene expression that ultimately assembles
three major dopaminergic circuits that are crucial for normal behaviour and physiological function [4,5].
These circuits are formed by the arrangement of midbrain dopaminergic (mDA) neurons into three dif-
ferent populations known as the A8, A9 and A10 groups [6]. mDA neurons in the A10 and A8 clusters
are, respectively, found in regions known as ventral tegmental area (VTA) and the retrorubral field (RRF).
VTA and RRF mDA neurons project to the nucleus accumbens, limbic system and prefrontal cortex via
the mesocortical and mesolimbic projections to regulate emotion, motivation and reward behaviours [7].
Consequently, alterations in mesocortical and mesolimbic mDA neuronal functioning have been impli-
cated in a range of psychiatric disorders including schizophrenia, drug addiction and depression [8,9].
The other population of mDA neurons, the A9 population, is located in a region of the midbrain called
the substantia nigra pars compacta (SNpc). These A9 mDA neurons project to and innervate the dor-
sal striatum (caudate-putamen) to form the nigrostriatal pathway, which has a well-established role in
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regulatingmotor function. It should be noted however that theA9mDAneuronal populationmay also play significant
roles in reward function [10] (for detailed review see [11]). A9 mDA neurons have been the focus of a considerable
research effort, as the progressive loss of these neurons is one of the core pathological features of the neurodegenerative
disorder, Parkinson’s disease (PD) [12–15]. Despite much progress in understanding the pathological basis of PD and
the molecular mechanisms involved [16], there is still no disease-modifying therapy.
Though various experiment therapies have been proposed for PD, the application of neurotrophic factors to the PD
brain has been the focus of intensive investigation [17]. Severalmembers of the transforming growth factor-β (TGFB)
superfamily are potent neurotrophic factors for mDA neurons [18]. These include glial cell line-derived neurotrophic
factor (GDNF) and neurturin (NTN), which have been tested in clinical trials [19]. Despite initial promising results,
these trials have not to date been successful [20,21]. Recent work has shown that the lack of efficacy of GDNF and
NTN may result from alpha-synuclein-induced down-regulation of their common co-receptor, Ret, which is crucial
for GDNF and NTN signalling [22] as GDNF did not confer neuroprotection in the α-synuclein rat model of PD
[23]. As such the authors of the latest adeno-associated virus (AAV)–NTN trial stated that “better results might be
achieved with other trophic factors that are not RET dependent” [21]. BMPs have been shown to exert neurotrophic
effects on mDA neurons in a Ret-independent manner.
In this review, we will: provide an overview of the bone morphogenetic proteins (BMPs) and their intracellular
signalling effectors, the Smads; review the evidence that these morphogens play an endogenous role in mDA neu-
rons; review the effects of BMPs onmDA neuron survival and axon growth; and highlight the potential of application
of BMP ligands or molecular targeting of Ret-independent BMP–Smad signalling as a potential neuroprotective ap-
proach to attenuate or stop the degeneration of A9 mDA neurons in PD.
BMP–Smad signalling
The TGFB superfamily is a large family of related growth factors comprised of at least 30 members in mammals. This
superfamily is subdivided into two functional groupings known as the TGFB-like group that includes TGFBs, ac-
tivins, nodals and some growth and differentiation factors (GDFs), and the BMP-like group that includes the BMPs,
most GDFs and anti-Mullerian hormone (AMH) (for excellent review see [24]). The BMPs and GDFs constitute the
largest subgroup of the TGFB superfamily, and BMP–Smad signalling functions in many crucial aspects of neural
development [25]. Although members of both the TGFB-like and BMP-like groups have been examined as neu-
rotrophic factors for mDA neurons [18,26], for the purposes of this review we will focus on three members of the
BMP-like group that have been extensively studied in this regard, namely BMP2 (HGNC:1069), BMP7 (HGNC:1074)
and GDF5, which is also known as BMP14 (HGNC:4220).
BMP ligands, as all TGFB superfamily members, signal through a canonical pathway involving a heteromeric com-
plex of type I (ACVR1, BMPR1A and BMPR1B) and type II (ACVR2A, ACVR2B and BMPR2) transmembrane ser-
ine/threonine kinase receptors that phosphorylate and activate intracellular effector proteins called Smads (Figure 1a)
[24]. These receptors can pair in various combinations with varying affinities for BMP ligands, but BMP2, BMP7 and
GDF5 can bind BMPR2 and ACVR2A and 2B [27,28], while BMP2 and BMP7 bind BMPR1A or BMPR1B recep-
tors with high affinity [29]. Interestingly, GDF5 binds BMPR1B and BMPR2, but not BMPR1A, with high affin-
ity (Figure 1b) [30]. BMP ligand binding results in type-I receptor phosphorylation that recruits and phosphory-
lates receptor-activated Smad proteins (R-Smads) (Figure 1c). These BMP-activated R-Smads (Smad1, Smad5 and
Smad8/9) complex with Smad4, after which this transcriptional complex accumulates in the nucleus, binds to DNA
and elicits a transcriptional response (Figure 1d). It should be noted that this is an overly simplistic view, as BMP
signalling is complex and is regulated at multiple levels through a number of different mechanisms (for detailed
reviews see [24,25]). In recent years, it has also emerged that BMPs can have context-dependent effects through
non-canonical pathways that include GTPases, MAPK and PI3K pathways [31–33]). Since the effects of BMPs on
mDA neurons are largely Smad-dependent [34,35], for the purposes of this review we will focus on describing the
contribution of the canonical BMP–Smad pathway to mDA neuronal survival and growth; however, understanding
the role of non-canonical BMP signalling is an important line of future investigation.
A role for endogenous BMP signalling in mDA neurons
The physiological role of BMP signalling in mDA neurons remains unclear, yet a number of lines of evidence suggest
that it is actively involved. Indeed, we have found that Bmpr2mRNA is stably expressed at high levels in rat midbrain
from embryonic day (E)14 through to adulthood [34]. Conversely, Bmpr1b mRNA is expressed at low levels at E14
rat midbrain, but there is a significant increase in its expression with advancing age that reaches maximal levels in
adulthood [34]. BMPR2 and BMPR1b are co-expressed in mDA neurons, as both receptors co-localize with tyrosine
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Figure 1. The canonical BMP–Smad signalling pathway
(a) Binding of BMP dimers induces heteromeric complex formation and activation of type I and type II BMPR via transphosphorylation.
These recruit R-Smads (Smad1/5) that, when phosphorylated, form heteromeric complexes with Co-Smad4, then translocate to the nu-
cleus, bind DNA and alter transcription. (b and c) Immunocytochemistry showing the subcellular localization of BMPR2 (green) and Smad1
(green) respectively, in A-431 and MCF7 cells stained for microtubules (red). Image credit: Human protein atlas www.proteinatlas.org [87].
Image data available from v16.proteinatlas.org at the following URLs: www.proteinatlas.org/ENSG00000204217-BMPR2/cell#human and
www.proteinatlas.org/ENSG00000170365-SMAD1/cell#human. (d) Representative images of SH-SY5Y cells transfected with a Smad-bind-
ing element (SBE)–GFP reporter plasmid, showing that BMP treatment leads to Smad-dependent transcription [34,38]; scale bar = 10 μm.
hydroxylase (TH)-stained embryonic and adult rat mDA neurons [34]. These data suggest that endogenous BMP
signalling may play a functional role in mDA neurons in vivo.
The strongest line of evidence supporting such a role comes from a study of BMPR2 dominant negative
(BMPR2DN) mice [36]. Adult male BMPR2DN mice had a 20% reduction in mDA neuron number, but an almost
complete loss (approximately 90%) of striatal innervation. BMPR2DN mice also demonstrated reduced locomotor
activity compared with their wild-type counterparts [36]. However as BMPR2 is strongly expressed throughout life
[34], it is unclear whether this reflects a role for BMP–Smad signalling in the development of mDA neurons, or a role
in their maintenance. While the two possibilities are not mutually exclusive, this is an important question to resolve,
as BMPs also play roles in the early development of other TH-positive (TH+ ) adrenergic neurons, which are also
affected in PD. Specifically, inhibition of global BMP signalling in the chick embryo by the BMP antagonist Noggin
prevented sympathetic neuron generation [37].Moreover, there is regional failure of sympathetic innervation, but not
survival, in mice that are either heterozygous or homozygous for the Gdf5bp null mutation [38], a frame-shift muta-
tion in the Gdf5 gene [39]. Specifically, there were sympathetic innervation defects without a change in the number
of the innervating neurons. This suggests that the nigrostriatal deficiencies seen in BMPR2DN mice may reflect a
role for BMP–Smad signalling in mDA neuronal development.With the generation of a number of BMPRflox/flox and
Smadflox/flox mouse lines (for review see [25]), injection of AAV encoding for Cre (AAV-Cre) to the SNpc of thesemice
would allow the contribution of BMP–Smad signalling to the maintenance of mDA neurons during adulthood to be
determined. The feasibility of this approach is highlighted in a recent elegant study that used intrastriatal injection of
AAV-Cre in GDNFflox/flox mice to examine the contribution of target-derived GDNF to mDA neuron maintenance
[40]. There has been only one study that examined theBMP ligands, which showed that adultBmp7+ / − heterozygous
mice (Bmp7− / − mice die with 24 h of birth) had a subtle loss of nigrostriatal innervation and were more vulnera-
ble to methamphetamine-induced mDA neuronal injury [41]. This suggests that endogenous BMP signalling has a
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
Licence 4.0 (CC BY).
3
Neuronal Signaling (2017) 1 NS20170027
DOI: 10.1042/NS20170027
significant role in protecting and maintaining adult mDA neurons in vivo. However, further study is required to de-
lineate the exact role of BMP–Smad signalling in mDA neuron development and/or maintenance, and to understand
the relative contribution and functional redundancy between BMP ligands and receptors in these processes.
Somal and axonal degeneration in PD
The progressive loss of A9 mDA neurons in PD leads to a loss of dopaminergic innervation and consequently
dopamine levels in the striatum. While there has been a historical focus on protecting the cell bodies of mDA neu-
rons, there is a growing awareness that early axonal degeneration may be central to PD progression (for review see
[42,43]). A quantitative study in humans has shown that there was a modest loss of TH+ dopaminergic axons in
the post-commissural putamen (striatum) at 1 year after PD diagnosis, while by 4 years post diagnosis there was a
complete loss of dopaminergic innervation [12]. Interestingly, while there was a marked reduction in mDA neurons
in the SNpc (50–90%) at the earliest times post diagnosis, there was little subsequent loss, and a residual population
of mDA neurons was still observed decades after diagnosis [12]. Therefore, it appears that while the loss of dopamin-
ergic innervation occurs rapidly and is completed by 4 years post diagnosis, the degeneration of mDA neurons lags
behind the axonal loss.When considering potential therapies for PD, it thusmay not be sufficient to stop the degener-
ation of the neuronal soma. Protecting the axons of the residual mDA neuronal population may also be an important
approach, given that a single A9 mDA neuron has a widespread and highly dense axonal arborization that can cover
approximately 2% of the striatum [44]. Moreover, the molecular mechanisms of degeneration of the neuronal soma
may be distinct from those that lead to axonal degeneration, as highlighted in animal models of PD.
Stereotaxic injection of 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle (MFB), striatum or SN
of adult rats induces the selective death of nigrostriatal dopaminergic neurons and is a commonly used animal model
of PD. Intrastriatal injection of 6-OHDA normally results in a rapid degeneration of mDA neurons in the SNpc
and their axonal terminals in the striatum, depending on the time the tissue is analysed after introduction of the
toxin [45]. Interestingly, there is complete protection of mDA neurons following intrastriatal 6-OHDA in Jnk2− / −
and Jnk3− /- mice but no protection of their axonal terminals [46], suggesting that there are distinct mechanisms
that mediate the degeneration of mDA neuron soma and of their axons [42,47,48]. This highlights the need to better
identify themolecularmechanisms that regulatemDAneuron survival and axon growth, and to translate this into new
neuroprotective therapies. Here, we review the evidence showing that BMPs can protect mDA neurons by promoting
both mDA neuron survival and axon growth in vitro and in vivo.
BMPs as neurotrophic factors for mDA neurons
The initial evidence for BMPs acting as neurotrophic factors for mDA neurons came from a study showing that treat-
ment of embryonic day E14 rat ventral mesencephalon (VM) cultures with BMP ligands led to significant increase
in mDA neuron survival. Specifically, treatment of these cultures with 10 ng/ml of BMP2 or BMP7 led to a 1.5-fold
increase in the number of mDA neurons after 7–8 days [49,50]. Interestingly, both BMP2 and BMP7 also increased
the number of astrocytes in these cultures, and inhibition of this increase in astrocyte number using the anti-mitotic
agents 5-fluorodeoxyuridine and α-aminoadipic acid inhibited the survival-promoting effects of BMP7 [49]. Simi-
larly, GDF5 also increased mDA neuronal survival and astroglial proliferation in E14 rat VM cultures [51–53]. How-
ever, inhibition of astroglial proliferation with antimitotic agents in GDF5- [54] or BMP2- [50] treated VM cultures
did not eliminate the survival-promoting effects of these BMPs. BMP2 and GDF5 also increased neuronal complex-
ity and promoted increases in neurite length and branching of mDA neurons in these cultures [50,52,55]. These data
suggested a direct effect of BMPs on mDA neurons, but the underlying molecular mechanisms and the contribution
of canonical Smad signalling to these effects remained unknown.
To begin to address this, we studied the effects of BMP2 and GDF5 (as the neurotrophic effects of these ligands
were not glial-dependent) using SH-SY5Y cells, a widely-used in vitro cell model of human dopaminergic neurons
[56,57]. This cell line expresses for BMPRs, Smad-1/5 and co-Smad4, and treatment of SH-SY5Y cells with BMP2 or
GDF5 led to a significant increase in total neurite length (Figure 2a) [35,58].Moreover, there was a significant increase
in phosphorylated (p)-Smad1/5 levels within 1 h of treatment [35]. Interestingly, the effects of BMP2 and GDF5 on
p-Smad1/5 and neurite growth were prevented by co-treatment with dorsomorphin, a small molecule inhibitor of
BMPR1A/B [35,59]. This suggested that the effects of BMP2 and GDF5 on neurite growth were mediated through
canonical BMPR-Smad signalling. In agreementwith this, transfection of SH-SY5Y cells with either a pcDNAplasmid
expressing a constitutively active BMPR1B (caBMPR1B) [60] or a control plasmid demonstrated that caBMPR1B
induced significant increases in p-Smad1/5 and neurite growth [35]. These effects were blocked by co-transfection
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Figure 2. BMPs are potent inducers of neurite growth in in vitro cellular models
(a) Representative photomicrographs of neurite length in BMP2- and GDF5-treated SH-SY5Y cells stained with the vital fluorescent dye
Calcein after 4DIV [35]. (b) Representative photomicrographs of single TH+ mDA neurons prepared from E14 rat VM, treated with 10 ng/ml
BMP2 or GDF5, as indicated, for 4DIV [34]; scale bar = 100 μm.
with siRNAs targeting the co-Smad4, to inhibit nuclear translocation of the Smad transcriptional complex [35]. These
data showed that BMPR1B-mediated activation of Smad signalling promoted neurite growth in SH-SY5Y cells.
However, it should be noted that while SH-SY5Y cells are useful models for studying molecular mechanisms, they
are ultimately neuroblastoma cells that recapitulate some, but not all, features ofmDAneurons. To address this directly
in mDA neurons, we studied individual mDA neurons in primary cultures of E14 rat VM. Similar to SH-SY5Y cells,
treatment with either BMP2 or GDF5 increased p-Smad1/5 levels and promoted survival [53] and neurite growth in
TH+ mDA neurons (Figure 2b) [34]. These effects of BMP2 and GDF5 were blocked by co-treatment with Noggin
and dorsomorphin, and mimicked by transfection with caBMPR1B. Moreover, transfection of individual cells with
siRNAs targeting BMPR1B or Smad4 prevented these effects [34]. These data showed that BMP ligand binding to
BMPR activates Smad signalling, which exerts a direct effect to promote axon growth in mDA neurons. Given these
findings and the significant loss of mDA axons in PD, targeting BMP–Smad signalling may be a useful therapeutic
approach to slow or prevent the loss of axons, or to promote the regrowth of axons from the residual population of
mDA neurons [12] that remain in the midbrain throughout the disease duration.
Despite these findings, it remains unclear whether the survival-promoting effects of BMPs on mDA neurons are
dependent on canonical Smad signalling [49–52]. This is an important question for future research given that there
may be distinct molecular mechanisms that regulate neuronal survival and axonal maintenance in mDA neurons
[46]. For example, a recent study that used another population of adrenergic neurons has shown that while GDF5,
acting in a retrogrademanner, promoted significant increases in axonal growth and branching of sympathetic neurons
(which are also affected in PD), it had no effect on their survival [38]. These effects were also mimicked by the
transfection of individual neurons with caBMPR1b. Moreover, the O’Keeffe et al. also directly tested the requirement
of Smad-dependent gene transcription for neurite growth, by co-transfecting with caBMPR1B and either a decoy
dsDNA-oligonucleotide containing the Smad consensus binding sequence (5′-gtacattgtcagtctagacataact-3′), which
sequesters activated R-Smads and prevents them from binding to DNA (Smad decoy) or a control oligonucleotide
with a scrambled sequence (control decoy). Similar to the effects in SHSY5Y cells [35] and mDA neurons [34], the
transfection of individual sympathetic neurons with caBMPR1B led to highly significant increase in neurite length,
branching and overall neurite arbour size and complexity, effects that were completely prevented by the Smad decoy
but not by the control decoy. This shows that the activation of canonical Smad signalling promotes axon growth
directly in neurons that are affected in PD. However, the contribution of canonical BMP–Smad signalling to mDA
neuron survival is an important question for future research. While the axon growth-promoting effects of BMPs may
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Table 1 Summary of the in vivo studies using BMPs in animal models of PD
Rotational (circling) behaviour in response to i.p. injection of amphetamine is widely used to assess the effects of treatments in rat models of
PD. Rats with a unilateral lesion of the nigrostriatal pathway display a distinct bias for the contralateral limbs, resulting in profound rotational
behaviour in a direction ipsilateral to the lesion following administration of amphetamine, which induces synaptic dopamine release, thus
stimulating locomotion. The symbol ‘ Rotations’ refers to a decrease in the mean number of amphetamine-induced rotations displayed
by the rats, indicating a protective effect on the lesioned nigrostriatal pathway.
Author, date
(reference
number)
Neurotoxin
(location) Neurotrophic factor Substantia nigra Striatum Motor function
Sullivan, 1997 6-OHDA (MFB) GDF5 (SN + LV) mDA neuron
survival
DA levels
DA turnover
DA terminals
Rotations
Sullivan, 1999 6-OHDA (MFB) GDF5 (SN or striatum
or LV)
mDA neuron
survival
DA levels
DA turnover
DA terminals
Rotations
Sullivan, 1998 6-OHDA (MFB) GDF5-treated E14 VM
grafts (striatum)
– – Rotations
Hurley, 2004 6-OHDA (striatum) GDF5 (SN or striatum) mDA neuron
survival
No effect on DA
terminals
Rotations
O’Sullivan, 2010 6-OHDA (striatum) GDF5-overexpressing
E13 VM cells
(striatum)
– – Rotations
Costello, 2012 6-OHDA (MFB or
striatum)
GDF5-overexpressing
CHO cells (SN or
striatum)
mDA neuron
survival
– Rotations
Zuch, 2004 6-OHDA (striatum) BMP7 (LV) TH
immunoreactivity
DA levels No effect on
locomotor activity
Harvey, 2004 6-OHDA (MFB) BMP7 (SN) TH
immunoreactivity
– Rotations
Espejo, 1999 6-OHDA (SN) BMP2-treated E14 VM
grafts (striatum)
– – Rotations
be dependent on their canonical Smad signalling pathway, whether this is the case formDAneuron survival currently
remains unknown.
Neuroprotective effects of BMPs in animal models of PD
In order to examine the potential of neurotrophic factors for clinical use in PD, studies on animal models are crucial.
Both GDF5 and BMP7 have been shown to induce neuroprotective effects on the nigrostriatal dopaminergic pathway
and to confer improvements in motor function in 6-OHDA rodent models of PD (Table 1).
Since BMPs do not cross the blood–brain barrier (BBB), it is necessary to administer these proteins directly into
the brain to examine their effects in vivo. Several studies have reported the potent neuroprotective effects of stereo-
taxic injection of recombinant human (rh)GDF5 into the 6-OHDA-lesioned adult rat brain. Intracerebral injection of
rhGDF5 protein has been shown to protect nigral dopaminergic neurons and their striatal terminals from 6-OHDA
lesion of the MFB [61,62]. In the clinical situation, PD patients have already experienced significant degeneration
of dopamine neurons prior to receive treatment. Thus, potential therapies are required to achieve restoration of the
nigrostriatal pathway in animal models. Injection of rhGDF5 protein into the striatum at one or two weeks after
intrastriatal 6-OHDA lesion has been shown to restore nigrostriatal dopaminergic integrity and function [63]. BMP
proteins are rapidly bio-metabolized in the brain and thus in order to explore the therapeutic potential of these agents,
it is important to investigate methods of achieving long-term delivery. Studies that implanted GDF5-overexpressing
embryonic mDA neurons [53] or an rhGDF5-overexpressing cell line [64] into the adult rat striatum showed signifi-
cantly preservation of the nigrostriatal mDA neuronal pathway after 6-OHDA lesions, with corresponding enhance-
ment of motor function.
BMP7 has also been reported to have neuroprotective effects in in vivo PD models. In the intrastriatal 6-OHDA
lesion rat model, intraventricular injection of BMP7 at one week post-lesion protected nigral dopaminergic neu-
rons, but had no effect on locomotor activity [65]. Another study found that pre-treatment with intranigral BMP7
6 c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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protected nigral dopaminergic neurons and striatal dopamine release from 6-OHDA-induced lesions of the nigros-
triatal pathway, as well as improving motor function in these rats [66]. These discrepancies may be as a result in
differences in the timing and site of BMP7 application among these studies.
One therapeutic approach for PD is cell replacement using grafting of embryonic mDA neurons into the adult
brain to replace those neurons that have been damaged by the disease. A limitation of this type of therapy is the low
survival rate of the grafted cells. A large research effort has investigated agents that could be used to improve cell
survival and several neurotrophic factors have shown promise in this application. Pre-treatment with either GDF5
[53,67] or BMP2 [68] has been shown to confer survival-promoting and function-enhancing effects on embryonic
rat mDA neurons after transplantation into the 6-OHDA-lesioned adult rat striatum.
The above studies illustrate the potential of the BMPs in the treatment of PD. However, the use of proteins as
therapeutic agents is limited by their rapidmetabolism in the brain. Furthermore, neuroprotective agents are generally
more efficacious at earlier stages of the disease, when the nigrostriatal pathway is relatively intact. Therefore the
potential effectiveness of BMP therapies declines as the disease progresses, and thus methods that ensure a sustained
and targeted supply of these agents to nigrostriatal dopaminergic neurons must be developed. One such approach
under investigation is gene therapy, which aims to introduce a long-term source of neurotrophic proteins to the brain,
and which has shown promise for PD (for review see [19]). Gene therapy using viral vectors to achieve an adequate
supply of BMPs to degenerating nigrostriatal neurons in the PD brain may be an optimal way of ensuring clinical
efficacy, even in advanced disease states. The neurotrophic factors GDNF and NTN have shown some promise in
clinical trials in PD patients, although problems with delivery, targeting and patient selection have meant that their
full potential has yet to be achieved (for review see [69]).
Small molecule approaches for targeting BMP–Smad
signalling
At present, direct injection into the brain is the only practical method of administrating viral vectors carrying neu-
rotrophic factors.While this approach is safe and clinically feasible in patients [70,71], it is reliant uponmDAneurons
in the PD brain maintaining expression of the full complement of proteins required to respond to the neurotrophic
factor. This challenge was highlighted by comprehensive studies that showed that GDNF failed to exert neurotrophic
effects on mDA neurons in the rat α-synuclein model of PD [23]. GDNF could not exert its neurotrophic effect in
this model due to α-synuclein-induced down-regulation of the GDNF receptor, Ret [55]. Furthermore, qualitative
studies in humans suggest that Ret is down-regulated in PD [22]. One approach to circumvent this problem would
be to bypass the need for neurotrophic factors or their receptors by selectively activating their downstream effectors.
Thus, identification of the signalling cascades that mediate the effects of neurotrophic factors may allow the devel-
opment of ligand–receptor-independent, non-invasive molecular therapies using small molecules or biologics that
cross the BBB. While this approach can be applied to any neurotrophic factor, we have recently begun to examine
the neuroprotective potential of targeting the downstream effectors of the BMP ligands in mDA neurons. Although
several inhibitors of canonical BMP-signalling pathway are known, including the synthetic antagonist dorsomorphin
[59], to date very few small molecules have been shown to activate canonical BMP signalling.
p300/CBPs are histone acetyltransferases (HATs) that act as transcriptional co-activator proteins, playing key roles
in the regulation of levels of transcriptional activity in response to diverse physiological stimuli [72]. p300/CBPs have
been shown to interact with Smad1 and Smad4 [73], and to activate BMP–Smad-mediated gene transcription [74]. As
Smad-mediated gene transcription is crucial for at least the axon growth-promoting effects of BMPs [38], targeting
p300/CBPs to activate BMP–Smad-mediated gene transcription may exert BMP-like neurotrophic effects in mDA
neurons. To provide proof-of-principle for this approach, we recently used a selective and potent small molecular ac-
tivator of p300/CBPs, known as CTPB (N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide)
[75]. Treatment of SH-SY5Y cells with 5μMCTBP led to a 1.5-fold increase in neurite growth [76], which is the same
level as that induced by GDF5 and BMP2 in SY-SY5Y cells [35] and mDA neurons [34]. Moreover, CTPB protected
against 6-OHDA-induced cell death in SY-SY5Y cells [76]. Although p300/CBP interacts with Smad1/Smad4 [73],
which are required for the axon growth-promoting effects of GDF5 [34,35,38], and activating p300/CBP activates
BMP–Smad-mediated gene transcription [74], it will be important to determine if the neurotrophic effects of CTBP
are dependent upon Smad-mediated gene transcription. Despite this, CTPB is a promising molecule for targeted in-
duction of p300/CBP activity in vivo, and ongoing studies will explore strategies for its delivery to the brain. For
example, CTPB conjugated to carbon nanospheres readily crosses the BBB and can localize in the brain [77]. Future
studies will focus on determining the neuroprotective efficacy of this approach in animal models of PD.
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Another molecular approach to activate BMP–Smad-dependent gene transcription in neurons may be to use hi-
stone deacetylase (HDACs) inhibitors (HDIs). HDIs are potent transcriptional modulators that inhibit HDACs to
increase transcription and cross the BBB [78]. The neurotrophic effects of HDIs on mDA neurons have been well
documented [79–83], andwe have recently shown that a class-IIa HDI promotes axon growth in SH-SY5Y cells, mDA
and sympathetic neurons, and protects them against MPP+ -induced degeneration [84]. While it is likely that diverse
molecular mechanismsmaymediate these effects, class-IIa HDAC inhibition led to a significant increase in the phos-
phorylation of Smad-1/5 in all three cell types [84]. This suggests that HDIs, which can cross the BBB, can increase
basal Smad-signalling in neurons in the absence of an exogenous BMP ligand. In future work, it will be important
to determine the contribution of increase in Smad signalling to the neurotrophic effects of HDIs on mDA neurons.
There is significant potential in a small molecule approach for clinical translation in neurodegenerative diseases. This
is highlighted by a Phase I trial investigating the ability of glycerol phenylbutyrate (an FDA-approvedHDI) to increase
the removal ofα-synuclein from the brain (NCT02046434) (https://clinicaltrials.gov/). If HDIs can be used to activate
canonical Smad signalling in mDA neurons in vivo, then they may have neurotrophic effects on mDA neurons and
therefore offer a non-invasive therapeutic approach. This will be an important question for future research; however,
the difficulty of this approach (as with any small molecule therapy) will be the specific targeting of mDA neurons to
limit potential side effects. The studies described above provide proof-of-principle that small molecules can be used
to activate BMP–Smad signalling, and thus that other similar molecules may be beneficial in PD.
Conclusions and future perspectives
As neurotrophic factors can promote mDA neuron survival and axon growth, neurotrophic factor therapy remains
promising for PD [17]. Despite the lack of efficacy of intracerebral AAV-NTN in a phase II trial, it is important to note
that post hoc analysis found that patients who had been diagnosed within 5 years of receiving AAV-NRTN treatment
showed significantly greater improvements in UPDRS scores than those who were diagnosed more than 10 years be-
fore [21]. This is an important consideration given that most patients display almost complete mDA axonal loss by
4 years post diagnosis [12]. It suggests that patients at the earlier stages of PD, when some of the nigrostriatal pathway
remains,may benefit themost fromneurotrophic factor therapy. Allied to this, it will also be important to improve our
understanding of the mechanisms of axonal degeneration and neuronal loss in PD. Is axonal degeneration a passive
event occurring as a consequence of somal injury, or a distinct process that can be targeted in addition to protecting
the soma? If the latter is the case, application of a single neurotrophic factor may not be the best approach. For exam-
ple, combined overexpression of two neurotrophic factors, cerebral dopamine neurotrophic factor (CDNF) and its
paralogue, mesencephalic astrocyte-derived neurotrophic factor (MANF), have synergistic effects on the nigrostri-
atal pathway in a rat model of PD [85]. However, the receptors and mechanisms of action of these two neurotrophic
factors have not yet been well characterized. Given the lack of efficacy of AAV-NTN to date [21] and the fact GDNF
ligands may not be able to signal in the PD brain due to down-regulation of Ret [22], it has recently been suggested
that ‘better resultsmight be achievedwith other trophic factors that are not Ret dependent’ and that ‘it might also be of
value to assess trophic factors in animal models that overexpress α-synuclein prior to initiating translational clinical
trials’ [21]. Given that BMP ligands have the same efficacy as GDNF in 6-OHDA animal models of PD [18,19], and
that their effects onmDA neurons are mediated in a Ret-independent manner through the Smad pathway [34], it will
be crucial to determine if BMPR expression or key downstream effector proteins are affected by α-synuclein, and if
the BMP ligands can exert neuroprotective effects in the α-synuclein model of PD. It is interesting to note that BMP2
has also recently been shown to up-regulate Nurr1 [86], raising the intriguing possibility that BMP ligands may re-
store responsiveness to the GDNF ligands, and highlighting the potential for combined neurotrophic factor therapy
to protect mDA axons as well as their neuronal soma. In addition, improving our understanding of the molecular
mechanisms mediating the neurotrophic effects of BMPs will be an important prerequisite for clinical translation.
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